Voyager Therapeutics, Inc. (VYGR): debt financing — Voyager Therapeutics expands leased space by ~61k SF; annual rent ~$4.9M starting June 2024

Voyager Therapeutics, Inc.

Total leased premises grows to 93,449 rentable SF (from ~32k SF) with addition of third floor.
Expansion rent commences June 2024 at $4,873,906.50 annual base rent, escalating ~3% annually through Jan 2031.
Landlord provides up to $1,839,210 tenant improvement allowance; tenant covers excess costs.
Security deposit letter of credit increased from ~$1.04M to ~$2.26M as of Jan 1, 2024.
Parking allocated to tenant increases from 75 to 228 spaces upon expansion commencement.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Voyager Therapeutics, Inc. amended lease obligation of Annual base rent of approximately $4.9 million increasing annually by approximately 3%; total commitment of ~$2.3 millio with LS 75 Hayden, LLC at Not applicable (lease) maturing January 31, 2031.

Instrument: lease obligation
Principal: Annual base rent of approximately $4.9 million increasing annually by approximately 3%; total commitment of ~$2.3 millio
Counterparty: LS 75 Hayden, LLC
Rate: Not applicable (lease)
Maturity: January 31, 2031
Event: amendment

Exact text from the filing

mendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”),

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Voyager Therapeutics, Inc. amended Lease Agreement with LS 75 Hayden, LLC (effective 2023-08-11).

Action: amendment
Agreement: lease
Counterparty: LS 75 Hayden, LLC
Effective: 2023-08-11

Exact text from the filing

On August 11, 2023, Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a first amendment (the “First Amendment”) to its existing lease agreement with LS 75 Hayden, LLC, as successor in interest to HCP/King 75 Hayden LLC (the “Landlord”), dated March 16, 2020 (the “Lease Agreement”)

View on SEC.gov

Browse all debt financings →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-092566

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.